Answer:
true
Explanation:
The use of the dapagliflozin SGLT2 inhibitor is beneficial to reduce hospitalizations for heart failure
The cardiovascular benefits of the drug for diabetes dapagliflozin extend over a wide spectrum of patients and are especially pronounced in those with reduced ejection fraction, a measure of the pumping capacity of the heart that indicates poor cardiac functioning,
The findings are derived from the 'DECLARE-TIMI 58' trial, which already showed in 2018 that dapagliflozin, part of a class of medications known as SGLT2 inhibitors, reduces the risk of cardiovascular death and hospitalizations for heart failure, regardless of ejection fraction or whether or not they had heart failure at the start of the study. However, the drug significantly decreased death rates from cardiovascular causes and death from all causes only among those who had a lower ejection fraction.
The use of the dapagliflozin SGLT2 inhibitor is beneficial to reduce hospitalizations for heart failure in patients with a wide range of left ventricular ejection fraction, but patients with reduced ejection fraction can obtain an even greater benefit.
